Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROWD: Durvalumab Consolidation After CRT and Surgery in Stage III NSCLC
NCT06908070Phase 4Recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of durvalumab in non-small cell lung cancer (NSCLC). Started Dec 2024; status: recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06908070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908070.